TürkiyeResearch and clinical trials
National health records: NMOSD affects about 2 in 100,000 people in Türkiye
A study published in a journal and reviewed by independent scientists. Even so, a single study is not conclusive; it needs to be replicated.
The ministry's national health records were searched. A total of 1,623 NMOSD patients were found. The disease affected 1.9 in 100,000 people. Its frequency decreased from east to west. The average age of patients was 44. Among antibody-positive patients, there were 8 women for every man. At least one preventive treatment had been given to 83% of patients.
What does it mean for patients and families?
This study is the first national NMOSD count in Türkiye. Because the numbers are based on registry codes, they are approximate. It may help with planning health services.
Source
Scientific paper: Prevalence and incidence of neuromyelitis optica spectrum disorder in Türkiye: A nationwide epidemiologic study. Multiple Sclerosis and Related Disorders, 2025. DOI: 10.1016/j.msard.2025.106383 · PubMed 40068231
The source page was opened and read on October 7, 2026. Summary prepared by the Doktorclub editorial team and translated from Turkish; it has not yet been reviewed by a physician (a scientific board is being set up).
This page is translated from the Turkish original.
Related disease: Neuromyelitis optica spectrum disorder (NMOSD)
This page reports a development; it is not a treatment recommendation. Your doctor decides whether a treatment is right for you.